The main shareholders implement a division of their

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
The main shareholders implement a division of their shareholdings in Recipharm

B&E Participation AB owns 12,685,716 shares series A and 3,892,407 shares series B in Recipharm, corresponding to approximately 46 percent of the capital and about 86 percent of the votes. Backsell Eldered Holding AB owns all the shares in B&E Participation AB. Lars Backsell and Thomas Eldered, founders of Recipharm, each own 50 percent of the shares in Backsell Eldered Holding AB. In the prospectus prepared in connection to the listing of Recipharm, dated 19 March 2014, it was announced that Lars Backsell and Thomas Eldered after the listing had the intention to split their shareholdings in Recipharm, meaning that B&E Participation AB transfers all shares held in Recipharm to companies directly or indirectly owned by Lars Backsell and Thomas Eldered, individually. In the prospectus it was further stated that Lars Backsell and Thomas Eldered had committed not to sell or otherwise transfer their respective shareholdings in Recipharm for a certain period after the first day of trading on NASDAQ OMX Stockholm (lock-up period), whereby Lars Backsell undertook a lock-up period of 18 months and Thomas Eldered a period of 36 months. Lars Backsell and Thomas Eldered have informed Recipharm that the split of shareholdings described above will be carried out. Initially, B&E Participation AB will distribute all shares in Recipharm which B&E Participation AB owns to its owner Backsell Eldered Holding AB. Thereafter, a demerger of Backsell Eldered Holding AB will be executed pursuant to Chapter 24 of the Swedish Companies Act, whereby half of the shares series A will be distributed to a new established limited liability company which by 100 percent will be owned by Lars Backsell and the other half of the shares will be distributed to a new established limited liability company which by 100 percent will be owned by Thomas Eldered. The shares of series B in Recipharm, currently owned by B&E Participation AB will, by the demerger of Backsell Eldered Holding AB, be distributed in such a way that 3,858,690 shares will be transferred to the company owned by Thomas Eldered and 33,717 shares to the company owned by Lars Backsell. After the completion of the above-mentioned transactions, Lars Backsell, through his wholly owned company, will own approximately 17 percent of the capital and about 42 percent of the votes in Recipharm. Thomas Eldered, through his wholly owned company, will own about 27 percent of the capital and about 44 percent of the votes in Recipharm. The Swedish Securities Council (AMN 2014:46) has granted Lars Backsell and Thomas Eldered exemption from the takeover rules which, according to Chapter 3, § 1 Stock Market (Takeover Bids) Act (2006:451), otherwise would arise from the division of shares in Recipharm AB as described above. The exemption also includes the right for Lars Backsell and Thomas Eldered, respectively, to acquire additional shares in Recipharm AB without triggering an obligation to launch an offer to acquire the shares of Recipharm AB. For further information, please contact: Lars Backsell, Chairman of the Board, lars.backsell@recipharm.com, telephone: +46 8 602 52 00 Thomas Eldered, CEO, Thomas.eldered@recipharm.com, telephone: +46 8 602 52 00 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ OMX Stockholm. This information was submitted for publication on 17th October 2014 at 14:00 CET. About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,750 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 250 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 2.6 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain and Italy and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro Telephone 46 8 602 52 00 Fax 46 8 81 87 03, www.recipharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 9

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 89

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 119

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 156

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 132

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

Gold's Surge and Euro's Stagnation Amid Economic Shifts

Updated Category News Views 261

Gold Gains Ground Amid Geopolitical Tensions Gold prices have recently shown an impressive rise, climbing 1.9% and breaking through the resistance level of $2,600. This rally followed a significant weekly decline in prices and reflects the market's reaction to ongoing geopolitical uncertainties. The surge in gold can be traced back to several influencing factors. One of...

Continue Reading
Teachable's Innovative Rebrand and Future Learning Vision

Updated Category News Views 209

Teachable's Innovative Rebrand and Future Learning Vision Teachable, a leader in online education, proudly announces a new visual identity and a striking product vision that redefines the learning experience for everyone. As the platform continues to evolve, the changes reflect a deep commitment to meeting the needs of today’s learners and educators. A New Identity for...

Continue Reading
Functionize Elevates Software Testing with Advanced AI Solutions

Updated Category News Views 169

Functionize Enhances Automation for Software Testing Automation Innovations Reshape Testing Using Natural Language Inputs to Create Reliable Tests and Streamline Complex Processes Across Enterprises Functionize, an innovative platform leveraging AI for software test case creation, has unveiled significant enhancements to its intelligent testing solutions. The recent...

Continue Reading
Anterix Inc. Delivers Strong Fiscal Performance This Quarter

Updated Category News Views 199

Anterix Inc. Highlights Its Fiscal Progress Anterix Inc. (NASDAQ: ATEX), based in Woodlang Park, has recently revealed impressive results for its second quarter of fiscal 2026. The company has filed its Form 10-Q, reflecting the financial performance for the three and six months leading to september 30, 2025. During this quarter, Anterix provided an update on its...

Continue Reading
10X Genomics Futures Brighten with New Single Cell Products

Updated Category News Views 80

10X Genomics Holds Steady with New Innovations 10X Genomics (NASDAQ: TXG) has received a reiterated Hold rating from TD Cowen, with a price target set at $20.00. This decision follows the company's announcement of plans to launch new Single Cell (SC) products during an industry event. The innovative products aim to provide cost-effective solutions focused on reducing...

Continue Reading